entertainment -WSS

entertainment

author：fashion 2025-08-31 21:00:09 - browse：35746

A woman walks in San Francisco, with her father who has Alzheimer's – public health and science coverage from STAT — Ben Margot/AP

A host of hurdles are slowing the adoption of the new Alzheimer’s drug Leqembi, experts involved in the treatment of patients said Wednesday, from complicated logistics to the fact that many people don’t recognize that their memory loss is a disease soon enough.

Some patients still grapple with whether they want to be diagnosed, even though a treatment exists, the experts said, speaking during a STAT virtual event.

“Even the word for dementia does not always exist in every culture and in every language,” said Hollis Day, chief of geriatrics at Boston Medical Center and a professor at Boston University’s medical school. “And so just getting people to accept that memory loss is not normal aging necessarily, is a big barrier to getting people into diagnosis early enough to benefit from these treatments.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Why palliative psychiatry is worth discussing

explore

focus

WSS

Antivenom research: Lessons from HIV applied in search for universal antidote

EMA weighs against approval for Mirati's lung cancer drug

Reframing the conversation around gain

Community Health Systems hospitals under DOJ investigation

Antivenom research: Lessons from HIV applied in search for universal antidote

Antivenom research: Lessons from HIV applied in search for universal antidote

entertainment

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Activists slam private health insurers over coverage restrictions

Alabama IVF ruling threatens families facing fatal genetic disease

Guidelines to prevent youth baseball injuries need more muscle

Antivenom research: Lessons from HIV applied in search for universal antidote

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Language on climate change, ESG removed from company website of Montana GOP Senate candidate

Anesthesiologist group: stop taking Ozempic before surgery

PBM reform efforts get punted in Congress

Hollywood unions extend contract negotiations for actors

Obesity drugs seen as possible treatment for liver disease MASH

hotspot

The Harvard botanist who searched for psychedelics in the Amazon

What is artificial intelligence? Experts weigh in

New documents shed light on MD Anderson Cancer Institute feud

Language on climate change, ESG removed from company website of Montana GOP Senate candidate

With competition flaring, obesity drug hits goal in liver disease study

New documents shed light on MD Anderson Cancer Institute feud

leisure time

explore

focus

focus